Merck KGaA, Darmstadt, Germany: Psoriasis trials

The registry lists 11 Psoriasis studies with Merck KGaA, Darmstadt, Germany as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 1Phase 3 3Phase 4 6No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis SubjectsCompletedNCT02156466Phase 1Results posted
• Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease RecurrenceCompletedNCT01079988Phase 4Results posted
• Raptiva in Palm and Sole PsoriasisTerminatedNCT00972543Phase 4Results posted
• TRUST Study: Raptiva ® in Hand & Foot PsoriasisTerminatedNCT00739882Phase 4Results posted
• ChangE From Any Systemic psoriasiS therapY to RaptivaTerminatedNCT00697593Phase 4Results posted
• A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT00287118Phase 4Results posted
• A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic TherapiesCompletedNCT00249808Phase 4Results posted
• Efalizumab for Treatment of Patients With Moderate to Severe PsoriasisCompletedNCT00442650Phase 3
• RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment OptimizationTerminatedNCT00402818
• CLEAR Study: Clinical Experience Acquired With Raptiva StudyCompletedNCT00256139Phase 3
• Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque PsoriasisTerminatedNCT00090129Phase 3